BioAge Labs, Inc.
$16.04
-3.0%BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -7.2).
Valuation inputs: P/E -7.2, earnings yield N/A, momentum -3.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -29.6%, ROIC -33.4%).
Profitability stack: net margin -9.0%, ROE -29.6%, ROIC -33.4%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +7.7%, momentum -3.0%, net margin -9.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
BioAge Labs, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
BioAge Labs, Inc. Fair Value Envelope
BioAge Labs, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
BioAge Labs, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
BioAge Labs, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
BioAge Labs, Inc. Street Expectations Map
Wall Street analysts project that BIOA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 42.20, with estimates ranging from a low of 23.00 to a high of 62.00.
The consensus 1-year price target stands at 42.20, with estimates ranging from a low of 23.00 to a high of 62.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
BioAge Labs, Inc. Insider Positioning
During the last 12 months, insiders have purchased $583K and sold $1.63M worth of BIOA shares, resulting in $1.04M of net selling activity.
3 Months
0
0.00
8.8K
157.08K
-157K
-$157K
3-6 Months
0
0.00
49.3K
767.12K
-767K
-$767K
6-9 Months
0
0.00
68.9K
701.91K
-702K
-$702K
9-12 Months
132.0K
583.44K
0
0.00
+583K
+$583K
Top Buyers
Enright Patrick G
Director
$98K
Garnier Jean Pierre
Director
$98K
Healy James
Director
$98K
Davidson Michael H.
Director
$98K
Hemrajani Rekha
Director
$98K
Top Sellers
Rubin Paul D
Officer: Chief Medical Officer
$1.46M
Goldstein Dov A Md
Officer: Chief Financial Officer
$165K
Insider Activity Analysis
Net Insider Sentiment
Negative insider sentiment with $1.04M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
No Dividend Yield Data
BIOA has not reported any dividend yield values in the available annual periods.
bioa Dividend History
Learning Layer
Related Guides
Build conviction on BIOA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.